<code id='80A24D4A90'></code><style id='80A24D4A90'></style>
    • <acronym id='80A24D4A90'></acronym>
      <center id='80A24D4A90'><center id='80A24D4A90'><tfoot id='80A24D4A90'></tfoot></center><abbr id='80A24D4A90'><dir id='80A24D4A90'><tfoot id='80A24D4A90'></tfoot><noframes id='80A24D4A90'>

    • <optgroup id='80A24D4A90'><strike id='80A24D4A90'><sup id='80A24D4A90'></sup></strike><code id='80A24D4A90'></code></optgroup>
        1. <b id='80A24D4A90'><label id='80A24D4A90'><select id='80A24D4A90'><dt id='80A24D4A90'><span id='80A24D4A90'></span></dt></select></label></b><u id='80A24D4A90'></u>
          <i id='80A24D4A90'><strike id='80A24D4A90'><tt id='80A24D4A90'><pre id='80A24D4A90'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:fashion    - browse:4
          Cambridge: Biogen
          Ruby Wallau for STAT

          Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

          The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

          advertisement

          HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus